5F-CUMYL-PEGACLONE

5F-CUMYL-PEGACLONE
Legal status
Legal status	CA: Schedule II; DE: NpSG (Industrial and scientific use only); UK: Under Psychoactive Substances Act;
Identifiers
	IUPAC name 2,5-Dihydro-2-(1-methyl-1-phenylethyl)-5-(5-fluoropentyl)-1H-pyrido[4,3-b]indol-1-one;
CAS Number	2377403-49-9;
PubChem CID	134818048;
ChemSpider	73962276;
UNII	7S7IFQ9PPG;
Chemical and physical data
Formula	C25H27FN2O
Molar mass	390.502 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES CC(C)(c1ccccc1)N4C=Cc3n(CCCCCF)c2ccccc2c3C4=O;
	InChI InChI=1S/C25H27FN2O/c1-25(2,19-11-5-3-6-12-19)28-18-15-22-23(24(28)29)20-13-7-8-14-21(20)27(22)17-10-4-9-16-26/h3,5-8,11-15,18H,4,9-10,16-17H2,1-2H3; Key:SMRRORRDOWXERZ-UHFFFAOYSA-N;

5F-CUMYL-PEGACLONE (5F-SGT-151, SGT-269) is a gamma-carboline based synthetic cannabinoid that has been sold as a designer drug, first being identified in Germany in 2017. It acts as a potent full agonist of the CB₁ receptor. ^[1]^[2] It appears to be more toxic than related compounds such as CUMYL-PEGACLONE, and has been linked to numerous serious adverse reactions, some fatal.^[3]

References

^ Mogler L, Halter S, Wilde M, Franz F, Auwärter V (2019). "Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE". Forensic Toxicology. 37 (1): 154–163. doi:10.1007/s11419-018-0447-4. PMC 6315001. PMID 30636984.
^ Janssens L, Cannaert A, Connolly MJ, Liu H, Stove CP (June 2020). "In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration". Drug Testing and Analysis. 12 (9): 1336–1343. doi:10.1002/dta.2870. hdl:1854/LU-8687072. PMID 32490586. S2CID 219285656.
^ Giorgetti A, Mogler L, Halter S, Haschimi B, Alt A, Rentsch D, Schmidt B, Thoma V, Vogt S, Auwärter V (2019). "Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE". Forensic Toxicology. 38 (2): 314–326. doi:10.1007/s11419-019-00514-w. hdl:11585/878663. S2CID 209449526.

This cannabinoid related article is a stub. You can help Wikipedia by expanding it.

[pmid30636984-1] Mogler L, Halter S, Wilde M, Franz F, Auwärter V (2019). "Human phase I metabolism of the novel synthetic cannabinoid 5F-CUMYL-PEGACLONE". Forensic Toxicology. 37 (1): 154–163. doi:10.1007/s11419-018-0447-4. PMC 6315001. PMID 30636984.

[pmid32490586-2] Janssens L, Cannaert A, Connolly MJ, Liu H, Stove CP (June 2020). "In vitro activity profiling of Cumyl-PEGACLONE variants at the CB1 receptor: Fluorination versus isomer exploration". Drug Testing and Analysis. 12 (9): 1336–1343. doi:10.1002/dta.2870. hdl:1854/LU-8687072. PMID 32490586. S2CID 219285656.

[3] Giorgetti A, Mogler L, Halter S, Haschimi B, Alt A, Rentsch D, Schmidt B, Thoma V, Vogt S, Auwärter V (2019). "Four cases of death involving the novel synthetic cannabinoid 5F-Cumyl-PEGACLONE". Forensic Toxicology. 38 (2): 314–326. doi:10.1007/s11419-019-00514-w. hdl:11585/878663. S2CID 209449526.

[1]

[2]

[3]

See also

References